RELATED STUDY
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
Key Findings: Research efforts of the past two decades have undoubtedly proven that cannabinoid signaling profoundly influences several aspects of the cutaneous biology, and its dysregulation is likely to contribute to the pathogenesis of several skin diseases. Although a number of open questions await to be answered, appropriate pharmacological modulation of the cutaneous cannabinoid signaling promises to be a powerful tool in treating such diseases.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Hungary
Year of Pub: 2019
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, O-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Pharma THC:CBD, Other Related Compounds, Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Unspecified
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, TRPV1, TRPV2, TRPV4, GPCR, TRPs, PPARs
